Rentosertib: phase IIa trial in IPF, target and molecule from generative AI
Status
Peer reviewed
Recorded on · biospace.com not confirmed
To be confirmed: seen only in a search-engine snippet.
- Announced
- Recordedpeer reviewed
What this status means
Source reading : Search-engine snippet only (level 1 of 3)
Published in a journal or reviewed by named experts.
The gist
Insilico Medicine announced on 3 June 2025 in Nature Medicine a phase IIa trial of rentosertib in IPF, with the target and the molecule coming from generative AI. Status: peer reviewed, not confirmed.
Cite this entry
A single status snapshot since Oct 11, 2026: a citation always points to a dated snapshot.
Cite snapshot 1, Oct 11, 2026
APA citation with the dated link
BibTeX @misc, key discoveria-insilico-rentosertib-r1
@misc{discoveria-insilico-rentosertib-r1,
author = {{DiscoverIA}},
title = {Rentosertib: phase IIa trial in IPF, target and molecule from generative AI},
howpublished = {DiscoverIA registry, entry insilico-rentosertib},
note = {Status « Peer reviewed », snapshot 1, recorded on October 11, 2026. new result},
year = {2026},
url = {https://discoveria.ai/en/fiche/insilico-rentosertib/#releve-1},
urldate = {2026-10-11}
}Dated link opens this snapshot in the history
Text written by an AI (DiscoverIA pipeline), on Reviewed by: nobody yetReport an error
What has not been reviewed?
The status and its sources come from the registry; only the explanatory text has not been reviewed. A reported error is corrected, then the text is reviewed.
The status and its sources come from the registry; only the explanatory text has not been reviewed. A reported error is corrected, then the text is reviewed.
Key facts
- Claimed by
- Insilico Medicine
announced on Jun 3, 2025 - Nature
- new result
- Field
- Biology and medicine (medicine / pharmacology)
- Checked by
- journal peer review (seen in a search-engine snippet); AJMC comment: preliminary results
- Sources (domains)
- 1 : 1 links only
- This entry
- AI draft, not reviewed
To understand
Analogy
It is like a building plan drawn with software: it still has to be built and tested, step by step, before anyone knows whether it holds.
What it changes
If the result holds, a molecule and its target, both from AI, would have reached the stage of a randomized trial in patients with idiopathic pulmonary fibrosis. A phase IIa is an early step: it is not an available treatment and efficacy is not established.
What remains unclear
The Nature Medicine publication was only seen in a search summary. An AJMC commentary calls the results preliminary, and the label of fully generative is the company's own description.
1 source.
For experts
Sources(domains)
- primaireinsilico.comlink only, reading not recorded
Method
Status “peer reviewed” recorded on 11 October 2026 from biospace.com (seen only in a search engine snippet).
Limits
This status is not confirmed: it rests on a search engine snippet.
It is like a building plan drawn with software: it still has to be built and tested, step by step, before anyone knows whether it holds.
Status history
Only one observation so far.
- 01
First observation:Peer reviewedCurrent statusnot confirmed
Source: biospace.comsearch-engine snippet only
An observation is added; none is ever erased.
Report an error or suggest a source
Thank you, your message was sent.
Sending failed. Try again, or write to [email protected].